Redeye initiates coverage of BICO, a leading player in the bioconvergence space. After a turbulent period, the company has taken steps to restore focus on return to growth and strengthen its balance sheet. This creates a turnaround opportunity that, if executed successfully, could justify significant multiple expansion from the current valuation of just around 1x current-year sales.

Read more and download the Research Report.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/